Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of gefitinib (an EGFR tyrosine kinase inhibitor), gemcitabine (a nucleoside analog), and nab-paclitaxel (an albumin-bound formulation of paclitaxel). This combination has been studied for the treatment of pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), particularly in patients with both cancers. The regimen works through multiple mechanisms: gefitinib inhibits EGFR signaling, gemcitabine disrupts DNA synthesis, and nab-paclitaxel interferes with microtubule function during cell division.
02
Targets
Beyond the preview
Go deeper on gefitinib + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + gemcitabine + nab-paclitaxel.